BioVision by Mirthulaa

🔍 Introduction In March 2025, the U.S. Food and Drug Administration (FDA) approved a groundbreaking gene therapy named Revakinagene Taroretcel, commercially branded as Encelto. Developed by Nanoscope Therapeutics, Encelto is the first allogeneic, cell-based gene implant therapy designed specifically to treat macular telangiectasia type 2 (MacTel type 2)—a rare degenerative retinal disorder with no previous approved treatment. This marks a monumental milestone in ophthalmic biotechnology, redefining the future of vision restoration for millions worldwide. 🧬 What is Macular Telangiectasia Type 2? MacTel type 2 is a rare, slowly progressive disease that affects the macula—the part of the retina responsible for sharp, central vision. It is characterized by: Dilation and leakage of small blood vessels, Gradual loss of photoreceptors, And eventual central vision impairment or blindness.There is no known cure or treatment—until now. 🧫 The Science Behind Encelto 🧠 Mechanism of Action: Ence...

The convergence of synthetic biology and wearable technology has given rise to one of the most fascinating innovations in biotechnology today — living tattoo biosensors. These are flexible, skin-applied patches that contain engineered living cells capable of sensing changes in the body or environment and producing a visible response. Unlike conventional sensors that depend on electronics or batteries, living tattoos operate autonomously using the metabolic activity of the cells embedded in them. At their core, living tattoo biosensors consist of a soft, biocompatible hydrogel matrix, such as alginate, into which genetically modified bacteria are embedded. These bacteria are programmed using synthetic gene circuits to detect specific molecules, such as glucose, pH changes, toxins, or even temperature. Upon sensing the target stimulus, the bacteria activate a reporter gene that leads to a visible output — typically a change in color or the emission of fluorescence. Since the design is mo...